"Thyroid eye disease is a lifelong autoimmune disease that can worsen or flare, regardless of how it has been treated," said George Kahaly, MD, PhD, professor of medicine and endocrinology at Johannes Gutenberg University Medical Center in Mainz, Germany. For their analysis, they analyzed pooled clinical trial data beyond the 24-week treatment period for patients who received the full course in the phase 2/3 studies.
Similar to week 24 results, 51 weeks after therapy most participants maintained response to teprotumumab for the composite outcome ; clinical activity score ; diplopia ; proptosis ; and overall response . Overall, during the 99 weeks of follow-up, the longest to date, 82% of 106 reporting patients did not need additional thyroid eye disease treatment post-teprotumumab therapy .
Adverse effects were consistent with the known safety profile of teprotumumab. Four cases of hyperglycemia were newly reported during the follow-up, three of which were resolved and one was ongoing, as the patient discontinued the study due to a flare. Three cases of"As physicians consider treatment approaches for their thyroid eye disease patients, they now have longer-term data to support the use of teprotumumab in appropriate patients," Kahaly said.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »